October 24, 2011
SymBio Pharmaceuticals announced on October 21 that its business partner in Taiwan, InnoPharmax Inc., has received approval for the malignant lymphoma treatment SyB L-0501 (bendamustine HCL) from the Taiwan Food and Drug Administration. The drug is indicated for indolent non-Hodgkin’s...read more